Stock listing
Turquoise:DXCMN DexCom, Inc. Share Price
UK listing (Turquoise) of DexCom, Inc. · home listing NASDAQ:DXCM
Follow DexCom, Inc. into a list and get an email when it puts out news.
Home listing price · NASDAQ:DXCM
$79.32 USD -3.20 (-3.9%)
Close on Nov 20, 2026 · This listing has no price on 6ix; the price shown is the home listing's, NASDAQ:DXCM
- Day range
- $78.75 – $81.58 USDNov 20, 2026
- Volume
- 4.61M sharesNov 20, 2026
- Market cap
- $29.58B USDAt the close on Nov 20, 2026 · price × 373.0M shares outstanding
- 52-week range
- $56.72 – $92.59 USDLowest and highest trades, Nov 21, 2025 – Nov 20, 2026
- Traded on an average day
- $354.1M USDMedian day 3.61M shares · last 3 months, Aug 20, 2026 – Nov 20, 2026

Prices by listing
| Listing | Last | Change | Volume | Open | High | Low | Previous close | Price from |
|---|---|---|---|---|---|---|---|---|
| NASDAQ:DXCM · Home | $79.32 USD | -3.20 (-3.9%) | 4,607,800 | $80.48 | $81.58 | $78.75 | $82.52 | Close on Nov 20, 2026 |
| B3:D1EX34 | 9.30 BRL | 0.00 (0.0%) | — | 9.30 | 9.30 | 9.30 | 9.30 | Close on Nov 19, 2026 |
| Frankfurt:DC4 | €72.00 EUR | -1.20 (-1.6%) | 122 | €72.80 | €73.40 | €72.00 | €73.20 | Close on Nov 20, 2026 |
| Munich:DC4 | €72.80 EUR | -3.00 (-4.0%) | — | €73.30 | €73.30 | €72.80 | €75.80 | Close on Nov 20, 2026 |
Daily closes
Last 3 months, Aug 20, 2026 – Nov 20, 2026 · NASDAQ:DXCM · USD, adjusted for splits
| Day | Close | Change | % | Open | High | Low | Volume |
|---|---|---|---|---|---|---|---|
| $79.32 | -3.20 | -3.9% | $80.48 | $81.58 | $78.75 | 4,607,800 | |
| $82.52 | +0.48 | +0.6% | $81.67 | $83.07 | $81.28 | 4,250,208 | |
| $82.04 | +0.43 | +0.5% | $82.21 | $84.02 | $81.56 | 4,583,543 | |
| $81.61 | -1.72 | -2.1% | $83.46 | $83.75 | $81.45 | 4,375,546 | |
| $83.33 | +1.94 | +2.4% | $82.01 | $83.66 | $81.39 | 3,013,567 | |
| $81.39 | +1.045 | +1.3% | $80.99 | $82.51 | $79.38 | 4,087,099 | |
| $80.35 | +0.425 | +0.5% | $79.80 | $80.58 | $78.93 | 3,231,195 | |
| $79.92 | -1.15 | -1.4% | $80.88 | $81.07 | $79.18 | 3,098,705 | |
| $81.07 | +1.66 | +2.1% | $80.48 | $81.45 | $79.31 | 4,098,909 | |
| $79.41 | -5.05 | -6.0% | $82.73 | $82.85 | $79.21 | 3,936,995 | |
| $84.46 | -4.02 | -4.5% | $89.58 | $90.25 | $83.33 | 4,899,646 | |
| $88.48 | +5.51 | +6.6% | $85.06 | $88.96 | $84.75 | 4,822,585 | |
| $82.97 | -1.79 | -2.1% | $84.55 | $85.18 | $82.81 | 4,123,104 | |
| $84.76 | +2.47 | +3.0% | $82.82 | $85.19 | $82.58 | 4,059,519 | |
| $82.29 | +2.36 | +3.0% | $81.52 | $85.25 | $79.79 | 8,637,191 | |
| $79.93 | +1.31 | +1.7% | $79.08 | $80.01 | $78.59 | 5,911,426 | |
| $78.62 | +0.06 | +0.1% | $78.19 | $79.41 | $77.69 | 5,370,036 | |
| $78.56 | -0.01 | 0.0% | $78.62 | $79.86 | $78.05 | 5,159,367 | |
| $78.57 | +0.63 | +0.8% | $77.25 | $78.58 | $76.52 | 6,026,136 | |
| $77.94 | -0.38 | -0.5% | $78.68 | $79.51 | $77.82 | 5,214,998 | |
| $78.32 | -1.94 | -2.4% | $79.90 | $80.49 | $77.11 | 10,794,300 | |
| $80.26 | -5.48 | -6.4% | $83.75 | $86.17 | $79.92 | 8,018,713 | |
| $85.74 | -0.24 | -0.3% | $86.11 | $87.08 | $85.14 | 2,393,137 | |
| $85.98 | -0.06 | -0.1% | $86.11 | $86.61 | $85.43 | 2,590,519 | |
| $86.04 | -1.67 | -1.9% | $87.93 | $88.87 | $85.80 | 3,583,400 | |
| $87.71 | +4.24 | +5.1% | $85.48 | $87.88 | $85.25 | 4,786,100 | |
| $83.47 | -1.59 | -1.9% | $85.89 | $86.18 | $83.30 | 3,479,900 | |
| $85.06 | -0.86 | -1.0% | $86.19 | $86.60 | $84.49 | 4,017,000 | |
| $85.92 | +1.81 | +2.2% | $84.60 | $86.10 | $84.21 | 2,991,800 | |
| $84.11 | -0.30 | -0.4% | $84.41 | $85.49 | $82.94 | 3,154,200 | |
| $84.41 | +0.11 | +0.1% | $84.01 | $84.54 | $83.08 | 3,607,100 | |
| $84.30 | +0.91 | +1.1% | $83.81 | $85.70 | $83.74 | 2,863,800 | |
| $83.39 | -3.51 | -4.0% | $86.28 | $86.75 | $82.86 | 3,574,700 | |
| $86.90 | +1.54 | +1.8% | $84.75 | $87.12 | $84.75 | 3,078,900 | |
| $85.36 | -0.87 | -1.0% | $86.67 | $86.67 | $84.80 | 2,204,400 | |
| $86.23 | -0.06 | -0.1% | $86.46 | $87.70 | $85.81 | 3,034,600 | |
| $86.29 | -0.35 | -0.4% | $86.21 | $86.75 | $85.26 | 3,474,500 | |
| $86.64 | -0.04 | 0.0% | $86.63 | $87.03 | $85.24 | 3,120,500 | |
| $86.68 | +0.06 | +0.1% | $86.87 | $87.34 | $85.27 | 3,411,300 | |
| $86.62 | -0.85 | -1.0% | $87.38 | $87.64 | $86.36 | 1,891,000 | |
| $87.47 | -0.26 | -0.3% | $87.68 | $88.00 | $86.88 | 2,141,700 | |
| $87.73 | -1.80 | -2.0% | $89.50 | $90.05 | $87.36 | 3,668,500 | |
| $89.53 | +0.36 | +0.4% | $89.12 | $90.39 | $88.18 | 7,296,000 | |
| $89.17 | -0.18 | -0.2% | $88.83 | $89.68 | $88.33 | 3,515,900 | |
| $89.35 | +1.42 | +1.6% | $87.83 | $89.92 | $87.39 | 14,573,000 | |
| $87.93 | +0.59 | +0.7% | $87.54 | $88.26 | $87.17 | 2,824,000 | |
| $87.34 | +0.89 | +1.0% | $86.05 | $88.79 | $86.05 | 3,616,800 | |
| $86.45 | +1.77 | +2.1% | $84.04 | $87.36 | $83.26 | 5,960,900 | |
| $84.68 | +1.65 | +2.0% | $83.92 | $84.98 | $83.76 | 2,540,900 | |
| $83.03 | -1.48 | -1.8% | $84.65 | $85.82 | $82.83 | 2,547,400 | |
| $84.51 | +0.63 | +0.8% | $83.27 | $84.82 | $82.29 | 3,539,800 | |
| $83.88 | -0.65 | -0.8% | $83.93 | $85.16 | $82.80 | 4,177,200 | |
| $84.53 | -3.37 | -3.8% | $86.59 | $86.75 | $84.24 | 8,224,100 | |
| $87.90 | -1.81 | -2.0% | $88.78 | $89.00 | $87.65 | 2,361,500 | |
| $89.71 | +0.02 | 0.0% | $89.73 | $91.00 | $89.05 | 1,677,900 | |
| $89.69 | -0.45 | -0.5% | $90.03 | $91.90 | $89.54 | 1,918,200 | |
| $90.14 | -0.92 | -1.0% | $90.83 | $92.34 | $89.91 | 2,151,600 | |
| $91.06 | +0.24 | +0.3% | $90.00 | $91.18 | $89.09 | 2,999,300 | |
| $90.82 | +1.53 | +1.7% | $89.81 | $90.84 | $88.83 | 2,546,700 | |
| $89.29 | +0.33 | +0.4% | $88.37 | $90.43 | $87.60 | 3,025,900 | |
| $88.96 | -0.20 | -0.2% | $88.17 | $89.76 | $87.51 | 3,822,600 | |
| $89.16 | -1.90 | -2.1% | $90.73 | $91.14 | $88.78 | 4,105,700 | |
| $91.06 | -1.28 | -1.4% | $92.30 | $92.59 | $91.03 | 4,451,300 | |
| $92.34 | +2.12 | +2.3% | $89.61 | $92.56 | $89.20 | 3,481,300 | |
| $90.22 | +0.34 | +0.4% | $89.42 | $91.39 | $89.28 | 5,164,500 |
Splits
1 split · NASDAQ:DXCM · every price before a split is adjusted for it
| Day | Ratio | What |
|---|---|---|
| 4-for-1 | Split |
- Ticker
- Turquoise:DXCMN
- Asset type
- Stock
- Sector
- Health care
- Industry
- Medical devices & supplies
- Exchange
- Turquoise
- Currency
- USD
What changed lately
Latest news release · Nov 19, 2026
Dexcom Marks Athenry Opening With Celebration of Commercial Production Milestone
Latest earnings call · Oct 29, 2026
DexCom (NASDAQ:DXCM) Q3 2026 Earnings Call
Replay and transcript
Latest deck · Oct 29, 2026
Q3 2026 Earnings Presentation
Earnings · 10 slides
Latest news
Dexcom Marks Athenry Opening With Celebration of Commercial Production Milestone
Nov 19, 2026
Closed $79.32 (-3.9%) on Nov 20, 2026
Dexcom Announces Upcoming Conference Presentation
Nov 10, 2026
Closed $79.92 (-1.4%) on Nov 10, 2026
Dexcom Invites the Global Diabetes Community to Share Their Stories Through A Letter to Diabetes Campaign
Nov 2, 2026
Closed $84.76 (+3.0%) on Nov 2, 2026
Dexcom Reports Third Quarter 2026 Financial Results
Oct 29, 2026
Closed $82.29 (+3.0%) on Oct 30, 2026
Dexcom G7 15 Day Continuous Glucose Monitoring System to Launch in Canada in November
Oct 28, 2026
Closed $78.62 (+0.1%) on Oct 28, 2026
Landmark Dexcom CONNECT Study Published in The New England Journal of Medicine, Redefining the Standard of Care for People with Type 2 Diabetes Not on Insulin
Oct 14, 2026
Closed $87.71 (+5.1%) on Oct 15, 2026
Dexcom Schedules Third Quarter 2026 Earnings Release and Conference Call for October 29, 2026 at 4: 30 p.m. Eastern Time
Oct 7, 2026
Closed $84.30 (+1.1%) on Oct 7, 2026
Dexcom U Enters Season 5 With a Record Roster and Evidence That Diabetes Stigma Among Young Athletes Is Fading
Oct 6, 2026
Closed $83.39 (-4.0%) on Oct 6, 2026
Dexcom Publishes New Report During EASD 2026 on Type 2 Diabetes Revealing Critical Opportunity for Global Diabetes Care
Sep 28, 2026
Closed $86.68 (+0.1%) on Sep 28, 2026
Dexcom Promotes Jereme Sylvain to Chief Operating Officer
Sep 14, 2026
Closed $86.45 (+2.1%) on Sep 15, 2026
DexCom, Inc. on 6ix
- Sector
- Health care
- Industry
- Medical devices & supplies
- News releases
- 36 in the last 12 months · 213 in all · newest Nov 19, 2026 · oldest 2019
- Calls
- 32 calls with a replay · 32 with a transcript · latest Oct 29, 2026
- Decks
- 45 decks · latest Oct 29, 2026
Where DexCom, Inc. is listed
| Listing | Exchange | Country | Currency |
|---|---|---|---|
| NASDAQ:DXCM · Home listing | NASDAQ | United States | USD |
| gettex:DC4 | gettex | Germany | EUR |
| LS Exchange:A0D9T1 | LS Exchange | Germany | EUR |
| Tradegate:DC4 | Tradegate | Germany | EUR |
| BMV:DXCM | BMV | Mexico | MXN |
| Lang & Schwarz:A0D9T1 | Lang & Schwarz | Germany | EUR |
| Dusseldorf:DC4 | Dusseldorf | Germany | EUR |
| B3:D1EX34 | B3 | Brazil | BRL |
| Frankfurt:DC4 | Frankfurt | Germany | EUR |
| BOATS:DXCM | BOATS | United States | USD |
| Milan:1DXCM | Milan | Italy | EUR |
| LSE:0A4M | LSE | United Kingdom | USD |
| Munich:DC4 | Munich | Germany | EUR |
| VIE:DXCM | Vienna | Austria | EUR |
| Hanover:DC4 | Hanover | Germany | EUR |
| Hamburg:DC4 | Hamburg | Germany | EUR |
| Stuttgart:DC4 | Stuttgart | Germany | EUR |
| Turquoise:DXCMN · This page | Turquoise | United Kingdom | USD |
| BIVA:DXCM | BIVA | Mexico | MXN |
| BX Swiss:DC4 | BX Swiss | Switzerland | CHF |
| SIX Swiss:DXCM | SIX Swiss | Switzerland | CHF |
| SIX Swiss:DXCM.USD | SIX Swiss | Switzerland | USD |
| Xetra:DC4 | Xetra | Germany | EUR |
Valuation
P/E 29.9× against a median of 27.9×: 7th lowest of 11 Medical devices & supplies companies shown. Statements: 4 quarters to Sep 30, 2026 · price Nov 20, 2026
- Enterprise value
- $28.62B USD
- P/E
- 29.9×
- EV/sales
- 5.6×
- EV/EBITDA
- No depreciation figure on 6ix yet
- Price/book
- 11.7×
- Gross margin
- 63.4%
- Operating margin
- 24.0%
- Net margin
- 19.4%
- Debt to equity
- 0.0×
- Beta vs S&P 500
- 0.71
Medical devices & supplies: the 10 companies nearest in size, of 448 on 6ix with figures. Size in US dollars.
| Company | Mkt cap | EV | P/E | EV/Sales | EV/EBITDA | P/B | Net mgn | Debt/Eq | Beta |
|---|---|---|---|---|---|---|---|---|---|
| DexCom, Inc. · NASDAQ:DXCM | US$29.58B | US$28.62B | 29.9× | 5.6× | n/a | 11.7× | 19.4% | 0.0× | 0.71 |
| Siemens Healthineers AG · XETR:SHL | US$52.77B | US$49.52B | 21.7× | 1.9× | 10.3× | 2.4× | 9.4% | 0.0× | n/a |
| GE HealthCare Technologies Inc. · NASDAQ:GEHC | US$36.46B | US$43.61B | 16.9× | 2.0× | 13.7× | 3.1× | 10.0% | 0.9× | 0.65 |
| Alcon AG · SIX:ALC | US$35.86B | US$38.74B | 54.0× | 3.5× | 16.1× | 1.6× | 6.1% | 0.2× | n/a |
| Shenzhen Mindray Bio-Medical Electronics Co., Ltd. Class A · SZSE:300760 | US$33.43B | US$30.45B | 28.7× | 5.9× | n/a | 5.4× | 22.4% | 0.0× | n/a |
| ResMed Inc. · NYSE:RMD | US$33.14B | US$32.54B | 20.8× | 5.7× | 15.6× | 5.6× | 27.8% | 0.1× | 0.48 |
| Koninklijke Philips N.V. · EURONEXT:PHIA | US$28.31B | US$34.23B | 27.0× | 1.8× | 10.0× | 2.2× | 5.4% | 0.7× | n/a |
| STERIS plc (Ireland) · NYSE:STE | US$24.94B | US$26.30B | 30.2× | 4.3× | 15.8× | 3.4× | 13.4% | 0.3× | 0.40 |
| Sonova Holding AG · SIX:SOON | US$20.69B | US$21.87B | 40.4× | 5.1× | 19.6× | 6.7× | 11.9% | 0.7× | n/a |
| Straumann Holding AG · SIX:STMN | US$20.27B | US$20.39B | 47.8× | 6.6× | 24.6× | 7.5× | 13.7% | 0.2× | n/a |
| Zimmer Biomet Holdings, Inc. · NYSE:ZBH | US$19.13B | US$26.24B | 24.9× | 3.1× | 11.6× | 1.5× | 8.9% | 0.6× | 0.40 |
| Median of the others | US$30.73B | US$31.50B | 27.9× | 3.9× | 15.6× | 3.3× | 10.9% | 0.2× | 0.44 |
Forecasts
22 strong buy · 4 buy · 3 hold · Analysts' consensus from EODHD, read Nov 22, 2026. Not 6ix's view and not investment advice.
- Price target
- 98.58 USD · Analysts' mean
- EPS, year to Dec 2026
- 2.70 · 25 analysts
- Revenue, year to Dec 2026
- 5.23B · 27 analysts
Team and board
Officers
| Officer | Role |
|---|---|
| Jacob Leach | President & Chief Executive Officer |
| Jereme Sylvain | EVP, Chief Operating Officer and Chief Financial Officer |
| Michael Brown | EVP, Chief Legal & Compliance Officer |
| Sean Christensen | INVESTOR RELATIONS |
| Jon Coleman | EVP, Chief Commercial Officer |
| Matthew Dolan | EVP, Strategy & Corporate Development |
| Peter Simpson | EVP, Chief Technology Officer |
| Sadie Stern | EVP, Chief People & Culture Officer |
Events
Calls
| Call | When | Status |
|---|---|---|
| DexCom (NASDAQ:DXCM) Q3 2026 Earnings Call | Thu, Oct 29, 2026 · 4:30 PM ET | Replay |
| DexCom (NASDAQ:DXCM) Q2 2026 Earnings Call | Thu, Jul 30, 2026 · 4:30 PM ET | Replay |
| DexCom (NASDAQ:DXCM) Q1 2026 Earnings Call | Thu, Apr 30, 2026 · 4:30 PM ET | Replay |
| DexCom (NASDAQ:DXCM) Q4 2025 Earnings Call | Thu, Feb 12, 2026 · 4:30 PM ET | Replay |
| DexCom (NASDAQ:DXCM) Q3 2025 Earnings Call | Thu, Oct 30, 2025 · 4:30 PM ET | Replay |
| DexCom (NASDAQ:DXCM) Q2 2025 Earnings Call | Wed, Jul 30, 2025 · 4:30 PM ET | Replay |
| DexCom (NASDAQ:DXCM) Q1 2025 Earnings Call | Thu, May 01, 2025 · 4:30 PM ET | Replay |
| DexCom (NASDAQ:DXCM) Q4 2024 Earnings Call | Thu, Feb 13, 2025 · 4:30 PM ET | Replay |
| DexCom (NASDAQ:DXCM) Q3 2024 Earnings Call | Thu, Oct 24, 2024 · 4:30 PM ET | Replay |
| DexCom (NASDAQ:DXCM) Q2 2024 Earnings Call | Thu, Jul 25, 2024 · 4:30 PM ET | Replay |
All 32 calls
Results days
| Quarter | Results | Share move |
|---|---|---|
| Q3 2026 | Oct 29, 2026 · After close | +3.0% |
| Q2 2026 | Jul 30, 2026 · After close | +11.9% |
| Q1 2026 | Apr 30, 2026 · After close | +3.0% |
| Q4 2025 | Feb 12, 2026 · After close | +7.6% |
| Q3 2025 | Oct 30, 2025 · After close | −14.6% |
| Q2 2025 | Jul 30, 2025 · After close | −9.3% |
| Q1 2025 | May 1, 2025 · After close | +16.2% |
| Q4 2024 | Feb 13, 2025 · After close | +5.9% |
| Q3 2024 | Oct 24, 2024 · After close | −1.9% |
| Q2 2024 | Jul 25, 2024 · After close | −40.7% |
All 20 quarters
| Quarter | Results | Share move |
|---|---|---|
| Q1 2024 | Apr 25, 2024 · After close | −9.9% |
| Q4 2023 | Feb 8, 2024 · After close | −5.2% |
| Q3 2023 | Oct 26, 2023 · After close | +10.1% |
| Q2 2023 | Jul 27, 2023 · After close | +2.3% |
| Q1 2023 | Apr 27, 2023 · After close | −1.8% |
| Q4 2022 | Feb 9, 2023 · After close | +9.9% |
| Q3 2022 | Oct 27, 2022 · After close | +19.4% |
| Q2 2022 | Jul 28, 2022 · After close | −5.6% |
| Q1 2022 | Apr 28, 2022 · After close | −1.1% |
| Q4 2021 | Feb 10, 2022 · After close | −4.9% |
Decks
| Deck | Kind | Slides | Date |
|---|---|---|---|
| Q3 2026 Earnings Presentation | Earnings | 10 slides | Oct 29, 2026 |
| Q2 2026 Earnings Presentation | Earnings | 10 slides | Jul 30, 2026 |
| Q2 2026 Earnings Presentation | Earnings | 94 slides | Jul 30, 2026 |
| Q1 2026 Earnings Presentation | Earnings | 10 slides | Apr 30, 2026 |
| Q4 2025 Earnings Presentation | Earnings | 10 slides | Feb 12, 2026 |
| Q4 2025 Earnings Presentation | Earnings | 25 slides | Feb 12, 2026 |
| Q3 2025 Earnings Presentation | Earnings | 11 slides | Oct 30, 2025 |
| Investor Presentation (October 2025) | Investor deck | 30 slides | October 2025 |
| Q2 2025 Earnings Presentation | Earnings | 11 slides | Jul 30, 2025 |
| Investor Presentation (July 2025) | Investor deck | 29 slides | July 2025 |
All 45 decks
Financials
Annual, in USD
Income statement
| Line | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | FY2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 4.66B | 4.03B | 3.62B | 2.91B | 2.45B | 1.93B | 1.48B | 1.03B | 718.5M | 573.3M |
| Cost of revenue | 1.86B | 1.59B | 1.33B | 1.03B | 768.0M | 646.6M | 544.5M | 367.7M | 226.4M | 194.9M |
| Gross profit | 2.80B | 2.44B | 2.29B | 1.88B | 1.68B | 1.28B | 931.5M | 663.9M | 492.1M | 378.4M |
| Research and development | 599.1M | 552.4M | 505.8M | 484.2M | 517.1M | 359.9M | 273.5M | 199.7M | 185.4M | 156.1M |
| Selling, general and administrative | 1.29B | 1.29B | 1.19B | 1.01B | 810.5M | 618.2M | 515.7M | 432.8M | 349.2M | 286.2M |
| Operating income | 911.8M | 600.0M | 597.7M | 391.2M | 265.8M | 299.5M | 142.3M | -186.3M | -42.5M | -63.9M |
| Depreciation and amortization | 251.8M | 217.7M | 186.0M | 155.9M | 102.0M | 67.1M | 48.7M | 29.1M | 16.1M | 15.0M |
| EBITDA | 1.16B | 817.7M | 783.7M | 547.1M | 367.8M | 366.6M | 191.0M | -157.2M | -26.4M | -48.9M |
| Interest expense | 18.3M | 19.0M | 20.3M | 18.6M | 18.8M | 17.7M | 60.3M | 22.7M | 12.8M | 700.0K |
| Income before tax | 1.09B | 709.0M | 710.4M | 390.8M | 256.8M | 297.9M | 104.2M | -126.5M | -48.6M | -64.9M |
| Income tax | 252.1M | 132.8M | 168.9M | 49.6M | 39.9M | -251.8M | 3.10M | 600.0K | 1.60M | 700.0K |
| Net income | 836.3M | 576.2M | 541.5M | 341.2M | 216.9M | 549.7M | 101.1M | -127.1M | -50.2M | -65.6M |
| Earnings per share, basic | 2.14 | 1.46 | 1.40 | 0.88 | 0.56 | 1.46 | 1.11 | -1.44 | -0.58 | -0.78 |
| Earnings per share, diluted | 2.09 | 1.42 | 1.30 | 0.82 | 0.53 | 1.33 | 1.10 | -1.44 | -0.58 | -0.78 |
Balance sheet
| Line | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | FY2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Cash and equivalents | 917.7M | 606.1M | 566.3M | 642.3M | 1.05B | 817.6M | 446.2M | 1.14B | 441.5M | 94.5M |
| Short-term investments | 1.73B | 2.16B | 1.81B | 1.36B | 92.7M | 107.1M | 29.2M | |||
| Receivables | 1.22B | 1.01B | 973.9M | 713.3M | 514.3M | 428.5M | 286.3M | 226.7M | 134.3M | 101.7M |
| Inventory | 629.1M | 542.6M | 559.6M | 306.7M | 357.3M | 234.7M | 119.8M | 70.7M | 45.2M | 45.4M |
| Current assets | 4.03B | 4.30B | 4.43B | 3.67B | 3.68B | 3.42B | 1.97B | 1.70B | 744.7M | 280.0M |
| Property, plant and equipment | 1.06B | 801.8M | 515.3M | 321.3M | 183.1M | 145.6M | 109.4M | |||
| Goodwill | 24.2M | 22.8M | 25.2M | 25.7M | 26.5M | 19.3M | 18.6M | 18.7M | 12.1M | 11.3M |
| Total assets | 6.34B | 6.48B | 6.26B | 5.39B | 4.93B | 4.29B | 2.40B | 1.92B | 904.1M | 402.8M |
| Current liabilities | 2.14B | 2.93B | 1.56B | 1.84B | 720.8M | 614.1M | 360.2M | 222.4M | 138.9M | 102.4M |
| Total liabilities | 3.59B | 4.38B | 4.20B | 3.26B | 2.89B | 2.46B | 1.51B | 1.25B | 484.7M | 119.0M |
| Shareholders' equity | 2.75B | 2.10B | 2.07B | 2.13B | 2.04B | 1.55B | 882.6M | 663.3M | 419.4M | 283.8M |
| Shares outstanding | 384.8M | 390.7M | 385.4M | 386.3M | 388.0M | 96.1M | 91.6M | 90.0M | 87.0M | 84.6M |
Cash flow
| Line | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | FY2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Cash from operations | 1.44B | 989.5M | 748.5M | 669.5M | 442.5M | 475.6M | 314.5M | 123.2M | 92.0M | 56.2M |
| Capital spending | -363.5M | -358.8M | -236.6M | -364.8M | -389.2M | -199.0M | -180.0M | -67.1M | -66.0M | -55.7M |
| Free cash flow | 1.08B | 630.7M | 511.9M | 304.7M | 53.3M | 276.6M | 134.5M | 56.1M | 26.0M | 500.0K |
| Cash from investing | 536.0M | -207.5M | -507.2M | -521.5M | -216.1M | -1.02B | -1.02B | -139.8M | -144.4M | -55.9M |
| Cash from financing | -1.69B | -734.8M | -318.6M | -552.5M | 10.4M | 912.1M | 10.7M | 710.4M | 399.1M | 8.10M |
| Share buybacks | -500.0M | -750.0M | -688.7M | -557.7M | 0 | 0 | 0 | -100.0M | 0 | 0 |
| Change in cash | 311.8M | 39.8M | -75.8M | -410.3M | 235.4M | 371.8M | -690.7M | 695.6M | 347.0M | 8.40M |
Filings
| Filing | Date | Type | Filed with |
|---|---|---|---|
| 4 · Change in ownership | Nov 18, 2026 | Insider trade | SEC |
| 144 · Notice of proposed sale | Nov 16, 2026 | Other filings | SEC |
| 4 · Change in ownership | Nov 10, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Nov 10, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Nov 10, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Nov 10, 2026 | Insider trade | SEC |
| SCHEDULE 13G · Big-stake notice | Nov 10, 2026 | Big-stake notice | SEC |
| 4 · Change in ownership | Nov 3, 2026 | Insider trade | SEC |
| 10-Q · Quarterly report | Oct 29, 2026 | Quarterly report | SEC |
| 8-K · Current report | Oct 29, 2026 | Results | SEC |
Show 200 filings
| Filing | Date | Type | Filed with |
|---|---|---|---|
| 4 · Change in ownership | Oct 28, 2026 | Insider trade | SEC |
| 144 · Notice of proposed sale | Oct 27, 2026 | Other filings | SEC |
| 4 · Change in ownership | Oct 19, 2026 | Insider trade | SEC |
| 144 · Notice of proposed sale | Oct 15, 2026 | Other filings | SEC |
| 4 · Change in ownership | Sep 30, 2026 | Insider trade | SEC |
| 144 · Notice of proposed sale | Sep 28, 2026 | Other filings | SEC |
| 4 · Change in ownership | Sep 16, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Sep 16, 2026 | Insider trade | SEC |
| 144 · Notice of proposed sale | Sep 15, 2026 | Other filings | SEC |
| 144 · Notice of proposed sale | Sep 15, 2026 | Other filings | SEC |
| 8-K · Current report | Sep 14, 2026 | Management or board change | SEC |
| 4 · Change in ownership | Sep 14, 2026 | Insider trade | SEC |
| 144 · Notice of proposed sale | Sep 14, 2026 | Other filings | SEC |
| 4 · Change in ownership | Sep 10, 2026 | Insider trade | SEC |
| 3 · Initial statement of ownership | Sep 10, 2026 | Insider trade | SEC |
| 8-K · Current report | Sep 10, 2026 | Management or board change | SEC |
| 144 · Notice of proposed sale | Sep 10, 2026 | Other filings | SEC |
| 4 · Change in ownership | Aug 28, 2026 | Insider trade | SEC |
| 144 · Notice of proposed sale | Aug 27, 2026 | Other filings | SEC |
| 4 · Change in ownership | Aug 25, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Aug 25, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Aug 25, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Aug 25, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Aug 24, 2026 | Insider trade | SEC |
| 144 · Notice of proposed sale | Aug 20, 2026 | Other filings | SEC |
| 4 · Change in ownership | Aug 17, 2026 | Insider trade | SEC |
| 144 · Notice of proposed sale | Aug 14, 2026 | Other filings | SEC |
| 4 · Change in ownership | Aug 13, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Aug 13, 2026 | Insider trade | SEC |
| 144 · Notice of proposed sale | Aug 12, 2026 | Other filings | SEC |
| 4 · Change in ownership | Aug 4, 2026 | Insider trade | SEC |
| 144 · Notice of proposed sale | Aug 3, 2026 | Other filings | SEC |
| 144 · Notice of proposed sale | Jul 31, 2026 | Other filings | SEC |
| 10-Q · Quarterly report | Jul 30, 2026 | Quarterly report | SEC |
| 8-K · Current report | Jul 30, 2026 | Results | SEC |
| 4 · Change in ownership | Jul 21, 2026 | Insider trade | SEC |
| 144 · Notice of proposed sale | Jul 20, 2026 | Other filings | SEC |
| 4 · Change in ownership | Jul 16, 2026 | Insider trade | SEC |
| 144 · Notice of proposed sale | Jul 15, 2026 | Other filings | SEC |
| 4 · Change in ownership | Jul 7, 2026 | Insider trade | SEC |
| 144 · Notice of proposed sale | Jul 6, 2026 | Other filings | SEC |
| 4 · Change in ownership | Jun 17, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Jun 17, 2026 | Insider trade | SEC |
| 144 · Notice of proposed sale | Jun 15, 2026 | Other filings | SEC |
| 144 · Notice of proposed sale | Jun 15, 2026 | Other filings | SEC |
| 4 · Change in ownership | Jun 5, 2026 | Insider trade | SEC |
| 144 · Notice of proposed sale | Jun 4, 2026 | Other filings | SEC |
| 144 · Notice of proposed sale | Jun 3, 2026 | Other filings | SEC |
| 4 · Change in ownership | Jun 1, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Jun 1, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Jun 1, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Jun 1, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Jun 1, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Jun 1, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Jun 1, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Jun 1, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Jun 1, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Jun 1, 2026 | Insider trade | SEC |
| 8-K · Current report | May 28, 2026 | Meeting outcome | SEC |
| SD · Specialized disclosure | May 28, 2026 | ESG report | SEC |
| 4 · Change in ownership | May 27, 2026 | Insider trade | SEC |
| 4 · Change in ownership | May 27, 2026 | Insider trade | SEC |
| 4 · Change in ownership | May 27, 2026 | Insider trade | SEC |
| 4 · Change in ownership | May 27, 2026 | Insider trade | SEC |
| 4 · Change in ownership | May 27, 2026 | Insider trade | SEC |
| 4 · Change in ownership | May 26, 2026 | Insider trade | SEC |
| 144 · Notice of proposed sale | May 21, 2026 | Other filings | SEC |
| 4 · Change in ownership | May 19, 2026 | Insider trade | SEC |
| 144 · Notice of proposed sale | May 15, 2026 | Other filings | SEC |
| 8-K · Current report | May 14, 2026 | Current report | SEC |
| 4 · Change in ownership | May 14, 2026 | Insider trade | SEC |
| 144 · Notice of proposed sale | May 12, 2026 | Other filings | SEC |
| 4 · Change in ownership | May 11, 2026 | Insider trade | SEC |
| 4 · Change in ownership | May 11, 2026 | Insider trade | SEC |
| 4 · Change in ownership | May 11, 2026 | Insider trade | SEC |
| 4 · Change in ownership | May 11, 2026 | Insider trade | SEC |
| 10-Q · Quarterly report | Apr 30, 2026 | Quarterly report | SEC |
| 8-K · Current report | Apr 30, 2026 | Results | SEC |
| SCHEDULE 13G · Big-stake notice | Apr 29, 2026 | Big-stake notice | SEC |
| SCHEDULE 13G · Big-stake notice | Apr 29, 2026 | Big-stake notice | SEC |
| 4 · Change in ownership | Apr 16, 2026 | Insider trade | SEC |
| ARS · Annual report to shareholders | Apr 15, 2026 | Annual report | SEC |
| DEFA14A · Additional proxy material | Apr 15, 2026 | Meeting notice | SEC |
| DEF 14A · Proxy statement | Apr 15, 2026 | Meeting notice | SEC |
| 144 · Notice of proposed sale | Apr 15, 2026 | Other filings | SEC |
| SCHEDULE 13G/A · Big-stake notice, amended | Mar 26, 2026 | Big-stake notice | SEC |
| 4 · Change in ownership | Mar 18, 2026 | Insider trade | SEC |
| 144 · Notice of proposed sale | Mar 16, 2026 | Other filings | SEC |
| 4 · Change in ownership | Mar 10, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Mar 10, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Mar 10, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Mar 10, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Mar 10, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Mar 10, 2026 | Insider trade | SEC |
| 8-K · Current report | Mar 2, 2026 | Management or board change | SEC |
| 4 · Change in ownership | Feb 26, 2026 | Insider trade | SEC |
| 3 · Initial statement of ownership | Feb 26, 2026 | Insider trade | SEC |
| 8-K · Current report | Feb 26, 2026 | Management or board change | SEC |
| 4 · Change in ownership | Feb 17, 2026 | Insider trade | SEC |
| 10-K · Annual report | Feb 12, 2026 | Annual report | SEC |
| 8-K · Current report | Feb 12, 2026 | Results | SEC |
| 144 · Notice of proposed sale | Feb 12, 2026 | Other filings | SEC |
| 4 · Change in ownership | Feb 2, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Feb 2, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Feb 2, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Feb 2, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Feb 2, 2026 | Insider trade | SEC |
| 8-K · Current report | Jan 12, 2026 | Results | SEC |
| 8-K · Current report | Dec 22, 2025 | Management or board change | SEC |
| 4 · Change in ownership | Nov 17, 2025 | Insider trade | SEC |
| 144 · Notice of proposed sale | Nov 14, 2025 | Other filings | SEC |
| 4 · Change in ownership | Nov 12, 2025 | Insider trade | SEC |
| 144 · Notice of proposed sale | Nov 12, 2025 | Other filings | SEC |
| 4 · Change in ownership | Nov 10, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Nov 10, 2025 | Insider trade | SEC |
| 144 · Notice of proposed sale | Nov 10, 2025 | Other filings | SEC |
| 10-Q · Quarterly report | Oct 30, 2025 | Quarterly report | SEC |
| 8-K · Current report | Oct 30, 2025 | Results | SEC |
| SCHEDULE 13G/A · Big-stake notice, amended | Oct 30, 2025 | Big-stake notice | SEC |
| 4 · Change in ownership | Oct 28, 2025 | Insider trade | SEC |
| 3 · Initial statement of ownership | Oct 28, 2025 | Insider trade | SEC |
| 8-K · Current report | Oct 27, 2025 | Management or board change | SEC |
| 8-K · Current report | Sep 15, 2025 | Management or board change | SEC |
| 4 · Change in ownership | Sep 9, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Sep 8, 2025 | Insider trade | SEC |
| 144 · Notice of proposed sale | Sep 5, 2025 | Other filings | SEC |
| 144 · Notice of proposed sale | Sep 4, 2025 | Other filings | SEC |
| 4 · Change in ownership | Sep 4, 2025 | Insider trade | SEC |
| 144 · Notice of proposed sale | Sep 2, 2025 | Other filings | SEC |
| 4 · Change in ownership | Aug 18, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Aug 18, 2025 | Insider trade | SEC |
| 144 · Notice of proposed sale | Aug 15, 2025 | Other filings | SEC |
| 144 · Notice of proposed sale | Aug 15, 2025 | Other filings | SEC |
| 10-Q · Quarterly report | Jul 30, 2025 | Quarterly report | SEC |
| 8-K · Current report | Jul 30, 2025 | Results | SEC |
| 4 · Change in ownership | Jul 29, 2025 | Insider trade | SEC |
| 144 · Notice of proposed sale | Jul 28, 2025 | Other filings | SEC |
| 4 · Change in ownership | Jul 17, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Jul 17, 2025 | Insider trade | SEC |
| 144 · Notice of proposed sale | Jul 15, 2025 | Other filings | SEC |
| 144 · Notice of proposed sale | Jul 15, 2025 | Other filings | SEC |
| 4/A · Change in ownership, amended | Jul 7, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Jun 30, 2025 | Insider trade | SEC |
| 144 · Notice of proposed sale | Jun 26, 2025 | Other filings | SEC |
| 4 · Change in ownership | Jun 18, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Jun 18, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Jun 17, 2025 | Insider trade | SEC |
| 144 · Notice of proposed sale | Jun 16, 2025 | Other filings | SEC |
| 144 · Notice of proposed sale | Jun 16, 2025 | Other filings | SEC |
| 144 · Notice of proposed sale | Jun 9, 2025 | Other filings | SEC |
| SD · Specialized disclosure | May 29, 2025 | ESG report | SEC |
| 4 · Change in ownership | May 28, 2025 | Insider trade | SEC |
| 4 · Change in ownership | May 28, 2025 | Insider trade | SEC |
| 144 · Notice of proposed sale | May 27, 2025 | Other filings | SEC |
| 4 · Change in ownership | May 27, 2025 | Insider trade | SEC |
| 144 · Notice of proposed sale | May 23, 2025 | Other filings | SEC |
| 8-K · Current report | May 13, 2025 | Management or board change | SEC |
| 4 · Change in ownership | May 12, 2025 | Insider trade | SEC |
| 4 · Change in ownership | May 12, 2025 | Insider trade | SEC |
| 4 · Change in ownership | May 12, 2025 | Insider trade | SEC |
| 4 · Change in ownership | May 12, 2025 | Insider trade | SEC |
| 4 · Change in ownership | May 12, 2025 | Insider trade | SEC |
| 4 · Change in ownership | May 12, 2025 | Insider trade | SEC |
| 4 · Change in ownership | May 12, 2025 | Insider trade | SEC |
| 4 · Change in ownership | May 12, 2025 | Insider trade | SEC |
| 4 · Change in ownership | May 12, 2025 | Insider trade | SEC |
| 4 · Change in ownership | May 12, 2025 | Insider trade | SEC |
| 8-K/A · Current report, amended | May 9, 2025 | Management or board change | SEC |
| S-8 · Registration statement for employee plans | May 9, 2025 | Offer document | SEC |
| 8-K · Current report | May 9, 2025 | Management or board change | SEC |
| DEFA14A · Additional proxy material | May 2, 2025 | Meeting notice | SEC |
| 8-K · Current report | May 2, 2025 | Management or board change | SEC |
| 10-Q · Quarterly report | May 1, 2025 | Quarterly report | SEC |
| 8-K · Current report | May 1, 2025 | Results | SEC |
| SCHEDULE 13G/A · Big-stake notice, amended | Apr 24, 2025 | Big-stake notice | SEC |
| 3 · Initial statement of ownership | Mar 31, 2025 | Insider trade | SEC |
| ARS · Annual report to shareholders | Mar 27, 2025 | Annual report | SEC |
| DEFA14A · Additional proxy material | Mar 27, 2025 | Meeting notice | SEC |
| DEF 14A · Proxy statement | Mar 27, 2025 | Meeting notice | SEC |
| 8-K · Current report | Mar 25, 2025 | Current report | SEC |
| 4 · Change in ownership | Mar 19, 2025 | Insider trade | SEC |
| 144 · Notice of proposed sale | Mar 17, 2025 | Other filings | SEC |
| 4 · Change in ownership | Mar 14, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Mar 14, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Mar 14, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Mar 14, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Mar 14, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Mar 11, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Mar 11, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Mar 11, 2025 | Insider trade | SEC |
This page holds 200 of 1,000 filings. Open Filings
Cap table
Built by 6ix from DexCom, Inc.’s releases · as of Oct 22, 2026
- Common shares
- 372,950,922
- Fully diluted
- 372,950,922
Fully diluted
| Line | Shares | As of |
|---|---|---|
| Common shares | 372,950,922 | Oct 22, 2026 |
Share count over time
| Count | Shares |
|---|---|
| Oct 22, 2026 | 372,950,922 |
People
6ix reads each seat by machine from the page it links to, and can misread one.
| Person | Seat |
|---|---|
| Quentin Blackford Other companies: Align Technology, Inc. (Director · Since at least Aug 27, 2026); iRhythm Holdings, Inc. (President, Chief Executive Officer and Director · Since at least Oct 4, 2021); Alphatec Holdings, Inc. (Director · Since at least Oct 2, 2017); Paragon 28 Inc (Director · Aug 1, 2022 – Apr 21, 2025 · Past); Axogen, Inc. (Director · Apr 26, 2019 – Mar 30, 2022 · Past); NuVasive Inc (CFO · Jul 1, 2016 – Feb 8, 2017 · Past) | Chief Operating Officer · Sep 7, 2017 – Sep 8, 2021 · Past |
| Bridgette Heller Other companies: Integral Ad Science Holding LLC (Director · Since at least Jun 29, 2021); Aramark (Director · Since at least Feb 2, 2021); Tech Data Corporation (Director · Nov 29, 2016 – Jun 30, 2020 · Past); ADT Inc. (Director · Sep 28, 2012 – May 2, 2016 · Past); Merck & Company, Inc. (Exe.VP & Pres.Con.Hlth.Care · Mar 1, 2010 – May 9, 2014 · Past) | Director · Since at least Sep 13, 2019 |
| Mark Foletta Other companies: Enanta Pharmaceuticals, Inc. (Director · Since at least Jun 29, 2020); AMN Healthcare Services Inc (Director · Since at least Nov 27, 2017); Tocagen Inc (EVP & Chief Financial Officer · Dec 8, 2017 – Oct 4, 2019 · Past); Regulus Therapeutics Inc (Director · Dec 4, 2017 – Dec 4, 2017 · Past) | Director · Since at least Nov 27, 2017 |
| Renée Galá Other companies: Jazz Pharmaceuticals plc (President & CEO, Director · Since at least Mar 16, 2020); Gossamer Bio, Inc. (Director · Feb 7, 2019 – Jun 8, 2023 · Past); Corcept Therapeutics Incorporated (Director · Mar 6, 2018 – Aug 20, 2018 · Past); Theravance Biopharma, Inc. (SVP, Chief Financial Officer · Nov 20, 2017 – Nov 20, 2018 · Past) | Director · Since at least Mar 6, 2025 |
| Sean Carney Other companies: Beta Bionics, Inc. (Board Member · Since at least Jan 29, 2025); MBIA Inc. (Director · Dec 12, 2013 – Jan 4, 2016 · Past); Wright Medical Group N.V (Director · Feb 2, 2011 – Mar 31, 2017 · Past); Arch Capital Group Ltd. (Director · May 3, 2006 – May 5, 2010 · Past) | Director · Jan 3, 2006 – May 19, 2008 · Past |
| Donald L Lucas Other companies: Spansion Inc (Director · Sep 20, 2007 – Aug 27, 2009 · Past); Cadence Design Systems, Inc. (Director · Apr 1, 2006 – Apr 2, 2012 · Past); Oracle Corporation (Director · Jan 31, 2006 – Jan 31, 2013 · Past) | Director · Jan 4, 2006 – Mar 15, 2010 · Past |
| Glenn Boehnlein Other companies: Agilent Technologies, Inc. (Director · Since at least Sep 4, 2026); Inogen, Inc (Director · Since at least Mar 22, 2022); Stryker Corporation (VP, Chief Financial Officer · Apr 1, 2016 – Mar 21, 2025 · Past) | Director · Since at least Sep 10, 2026 |
| Heather S Ace Other companies: PENN Entertainment, Inc. (Director · Since at least Feb 22, 2026); QUALCOMM Incorporated (EVP, Chief HR Officer · Since at least Mar 23, 2020) | SVP Human Resources · Aug 23, 2019 – Mar 11, 2020 · Past |
| Karen M Dahut Other companies: Tech Data Corporation (Director · Jun 6, 2018 – Jun 30, 2020 · Past); Booz Allen Hamilton Holding Corporation (Executive Vice President · Oct 3, 2017 – Jun 30, 2022 · Past) | Director · Aug 11, 2020 – May 8, 2025 · Past |
| Steven J Kemper Other companies: Constellation Alpha Capital Corp (Chief Financial Officer · Aug 29, 2019 – Aug 29, 2019 · Past); GenMark Diagnostics Inc (CFO, Treasurer & Secretary · May 28, 2010 – Sep 8, 2010 · Past) | Chief Financial Officer · Jan 5, 2006 – May 15, 2007 · Past |
All 49 people
| Person | Seat |
|---|---|
| Teri Lawver Other companies: Celldex Therapeutics, Inc. (Senior Vice President, Chief Commercial Officer · Since at least Nov 10, 2025); Altimmune, Inc. (Director · Since at least Feb 24, 2025) | EVP Chief Commercial Officer · Jan 9, 2023 – Mar 12, 2024 · Past |
| Andrew K Balo Other companies: GlucoTrack, Inc. (Director · Jun 14, 2024 – Mar 26, 2025 · Past) | EVP Regulatory Strategy Clinic · May 2, 2006 – Mar 10, 2023 · Past |
| Andrew P Rasdal Other companies: Vyome Holdings, Inc. (President, CEO & Exec Chairman, Director · Oct 5, 2016 – Jun 23, 2020 · Past) | President & CEO · May 2, 2006 – May 2, 2006 · Past |
| Chad Patterson Other companies: iRhythm Holdings, Inc. (Chief Commercial and Product Officer · Since at least Jul 25, 2022) | EVP Global Marketing · Mar 31, 2021 – May 9, 2022 · Past |
| Donald Abbey Other companies: ICU Medical, Inc. (Independent Director · Since at least May 15, 2019) | EVP Global Business Services I · Jun 3, 2019 – Mar 10, 2023 · Past |
| Euan Ashley Other companies: AstraZeneca PLC (Non-Executive Director · Since at least Nov 5, 2026) | Director · Since at least Oct 24, 2025 |
| Jacob Leach Other companies: SenesTech, Inc. (Director · Since at least Jul 1, 2022) | President & Chief Executive Officer · Since at least Mar 6, 2023 |
| Jereme Sylvain Other companies: NuVasive Inc (Chief Accounting Officer · Aug 1, 2016 – Feb 1, 2018 · Past) | EVP, Chief Operating Officer and Chief Financial Officer · Since at least Mar 6, 2020 |
| Jess Roper Other companies: Revelation Biosciences, Inc. (Director · Since at least Jan 10, 2022) | Former SVP, CFO · Jul 31, 2007 – Apr 1, 2017 · Past |
| John Lister Other companies: BillionToOne, Inc. (Chief Administrative Officer · Since at least Nov 5, 2025) | General Manager, EMEA · Mar 8, 2011 – Mar 8, 2017 · Past |
| Jon Coleman Other companies: Masimo Corporation (Pres-WW OEM & Global Health · Aug 11, 2008 – Feb 26, 2021 · Past) | EVP, Chief Commercial Officer · Since at least Mar 31, 2025 |
| Kyle Malady Other companies: Verizon Communications Inc. (Executive Vice President and CEO Verizon Business Group · Since at least Oct 1, 2020) | Director · Since at least Oct 11, 2020 |
| Rimma Driscoll Other companies: Zoetis Inc. (Executive Vice President, Global Strategy, Portfolio Marketing, Business Development, Human Health and Platinum Performance · Since at least Nov 1, 2022) | Director · Since at least Aug 24, 2023 |
| Steven Robert Pacelli Other companies: ProSomnus, Inc. (Director · Dec 6, 2022 – Feb 16, 2024 · Past) | EVP Managing Director Dexcom V · Apr 25, 2022 – Nov 24, 2023 · Past |
| Terrance H Gregg Other companies: Amylin Pharmaceuticals LLC (Director · Dec 31, 2005 – Apr 5, 2006 · Past) | Former Executive Chairman, Director · Jan 3, 2006 – Jul 30, 2018 · Past |
| Albert Frederick Osterloh IV | Director · Since at least Feb 26, 2026 |
| Barbara Kahn | Director · May 18, 2024 – May 18, 2024 · Past |
| Eric Topol | Director · May 20, 2022 – May 8, 2025 · Past |
| Girish Naganathan | EVP Chief Technology Officer · Oct 5, 2022 – Nov 9, 2023 · Past |
| James H Brauker | VP Research & Development · Feb 1, 2006 – Mar 24, 2008 · Past |
| Jeffrey Moy | EVP Operations · Mar 8, 2012 – Sep 9, 2020 · Past |
| Jon Coleman | EVP, Chief Commercial Officer · Since at least Mar 25, 2025 |
| Jorge A Valdes | Former CTO · Aug 2, 2007 – Mar 31, 2017 · Past |
| Kevin Sayer | Chair · Since at least Jan 7, 2026 |
| Laura Johnson | V.P., Intellectual Property · Sep 25, 2008 – Mar 12, 2010 · Past |
| Matthew Dolan | EVP, Strategy & Corporate Development · Since at least Mar 4, 2022 |
| Michael Brown | EVP, Chief Legal & Compliance Officer · Since at least Jan 26, 2022 |
| Nicholas Augustinos | Director · Since at least May 19, 2010 |
| Nick Augustinos | Director · Since at least Sep 16, 2026 |
| Paul R Flynn | EVP Global Revenue · Mar 31, 2021 – Dec 18, 2023 · Past |
| Peter Simpson | EVP, Chief Technology Officer · Since at least Nov 19, 2025 |
| Richard Collins | Director · Since at least Mar 9, 2017 |
| Richard Doubleday | EVP Chief Commercial Officer · Jun 22, 2009 – Mar 23, 2021 · Past |
| Rick Osterloh | Director · Since at least Feb 26, 2026 |
| Sadie Stern | EVP, Chief People & Culture Officer · Since at least May 22, 2026 |
| Sean Christensen | INVESTOR RELATIONS · Since at least Jul 30, 2026 |
| Steven R Altman | Director · Since at least May 8, 2025 |
| Steven R. Altman | Director · Since at least Jun 1, 2026 |
| Tae Andrews | Vice President of Marketing · Apr 3, 2006 – Mar 9, 2007 · Past |
Log in to ask 6ix AI your own questions about DexCom, Inc.